Baxter has acquired the Hospira Aseptic Services compounding business from Pfizer following approval from the Competition and Markets Authority
Facility enhances Baxter’s commitment to supporting the NHS in the provision of aseptic compounding services
Acquisition supports Baxter’s long term strategy to work with the NHS to reduce medication errors, freeing up time for clinicians and enabling more patients to receive treatment at home
COMPTON, UK - December 17, 2018
Baxter Healthcare Ltd, a leading medical products company, announced today the acquisition of Hospira Aseptic Services compounding business from Pfizer. This acquisition follows approval being granted by the Competition and Markets Authority. Terms of the agreement were not disclosed.
The modern facility is based in Croydon, and currently provides aseptically prepared chemotherapy, monoclonal antibodies and centralised intravenous additives to hospitals across the UK and Ireland. Through this acquisition, Baxter will be able to expand its aseptic compounding services to continue to meet the needs of our customers and patients.
“Adding the Croydon facility to Baxter’s network enables us to better support the NHS to meet growing demand for aseptic services and products, empower more patients to receive treatment at home, and help reduce medication errors,” said Andy Goldney, General Manager, Baxter UK, Ireland and Nordic. “This acquisition aligns with our broader strategy to help clinicians focus their time more on patient care rather than drug preparation.”
Aseptic compounding involves the reconstitution or ‘mixing’ of drugs into ready-to-use intravenous (IV) preparations for both hospital and home patient treatments, e.g. IV chemotherapy and home IV antibiotics. Reconstitution by commercial providers is conducted in a clean room environment utilising a highly regulated aseptic process and standards. Baxter utilises pharmaceutical drug vials from many sources, including drugs from its own pharmaceuticals division and third parties, which are then aseptically reconstituted for both NHS and private hospitals.
The Croydon facility joins Baxter’s four existing aseptic compounding units in the UK providing chemotherapy, monoclonal antibodies, and parenteral nutrition products. Each of Baxter’s compounding facilities in the UK are licensed by the MHRA, and supported by a Global Quality Assurance and Regulatory infrastructure as well as a European Research and Development facility with a specific focus on drug stability studies.
About Baxter Aseptic Compounding Services
For more than 30 years, Baxter has been a leading provider of a comprehensive range of outsourced aseptic preparations and services, and has forged lasting partnerships with the NHS and the private sector, including dedicated NHS aseptic units. With modern manufacturing facilities and broad expertise, Baxter is relied upon by hospitals across the UK to provide tailored, seamless medication compounding services.
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. Baxter is a registered trademark of Baxter International Inc.
Baxter is a registered trademark of Baxter International Inc.